Prosecutors examining fatal BIA-10-2474 trial start manslaughter investigation

By Gareth Macdonald contact

- Last updated on GMT

French authorities have started a manslaughter investigation in connection with a Ph I trial conducted by Rennes-based CRO Biotrial in which one volunteer died and five others were hospitalised.

The Paris public prosecutor's office announced the investigation today.

It said while the death and injuries that occured could have been the result of pre-existing medical conditions the men involved had been suffering, it decided to examine if “criminal offenses" ​had contributed.

Investigations​ conducted since the trial was halted in January show the drug the injured men received - BIA 10 2074 - was not adulterated and was given in the dosages specified in the ANSM-approved protocol.

A defendant in the case was not named.

Biotrial told us “This is a normal decision, which was expected as part of a complex investigation that requires expertise and investigations abroad. As we have done since the first day of the administrative and judicial investigations, we will continue to cooperate in the utmost transparency with investigators.

"The judicial investigation guarantees respect for the adversarial principle and the rights of people, which are highly valued. We are convinced that Justice alone will make the truth about this dramatic accident, truth which is owed to the victims and their families, but also to all the Biotrial staff.”


One man died and five others were hospitalised during the study of Portuguese drug firm Bial-Portela & Ca. SA's anxiety treatment candidate - BIA 10 2074 - in January​.

Last month, investigators from France's social affairs inspectorate (IGAS) criticised CRO Biotrial over how it conducted the Phase I study in a report (here​ – in French). 

Failings cited by IGAS included that Biotrial continued to administer the drug to volunteers after the first member of the group was sent to hospital and that it failed to confirm patient consent.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us


View more